

Press Release: Software as a Service (SaaS)

20/20 GeneSystems Partners with HealthLeader to Market OneTest in Taiwan

Gaithersburg, MD – June 28, 2024 – 20/20 GeneSystems, Inc., a leader in multi-cancer early detection technology, is pleased to announce a new strategic partnership with HealthLeader, a prominent healthcare provider in Taiwan. This collaboration aims to bring the innovative OneTest™ cancer screening technology to the Taiwanese market.

Expanding Access to Advanced Cancer Detection

HealthLeader, which collaborates with several TAF-certified medical laboratories, and these laboratories work with approximately 3,000 clinics in Taiwan, serving over 3 million people, will now incorporate 20/20 GeneSystems' OneTest™ technology into its offerings. This partnership will enable more people in Taiwan to benefit from early cancer detection through advanced algorithms and multi-biomarker analysis.

20/20 GeneSystems' Role

Under this agreement, 20/20 GeneSystems will provide Software as a Service (SaaS) and license its proprietary OneTest™ algorithms to HealthLeader. HealthLeader will utilize these algorithms to run the tests within their laboratories, ensuring local clinics and patients have access to state-of-the-art cancer screening.

A Step Forward in Cancer Prevention

This partnership marks a significant step in 20/20 GeneSystems' mission to make early cancer detection accessible to more people around the globe. By leveraging HealthLeader's extensive network and local expertise, OneTest™ will help identify cancer at its earliest stages, improving outcomes and saving lives.

"We are thrilled to partner with HealthLeader and bring our OneTest™ technology to Taiwan," said Jiming Zhou, PhD, COO of 20/20 GeneSystems. "This collaboration will allow us to expand our reach and provide critical early detection services to millions of people."

About HealthLeader

In Taiwan, HealthLeader collaborates with several TAF-certified medical laboratories, and these laboratories work with approximately 3,000 clinics nationwide, serving over 3 million people. HealthLeader has developed the "Medical Information Service Platform," which has obtained ISO 27001:2022 information security management system and ISO 27701:2019 privacy information management system international dual certifications. Additionally, they have created the "Health Action Go" app to provide comprehensive health management services. Through digital platforms, HealthLeader not only assists

medical professionals in improving work efficiency but also helps the public manage their health, achieving the goal of intelligent medical services.

<https://www.weleader.com.tw/About/Page/e2a04835-49f9-4914-ef75-08dc73f89f9a>

About 20/20 GeneSystems, Inc.

20/20 GeneSystems, Inc. is a pioneering company in multi-cancer early detection. Utilizing advanced algorithms and multi-biomarker analysis, 20/20 GeneSystems' OneTest™ offers a non-invasive, cost-effective solution for early cancer detection, helping to improve patient outcomes through timely intervention.

For more information, please contact:

Jiming Zhou, PhD
jzhou@2020gene.com
240-907-6999